Journal: Cancer discovery
This report describes results from the phase III lidERA trial evaluating giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant endocrine therapy for hormone receptor–positive breast cancer.
Key points:
- Giredestrant efficacy: Giredestrant improved invasive disease-free survival compared with standard adjuvant endocrine options (tamoxifen, letrozole, anastrozole, or exemestane).
- First advance in 20 years: The benefit represents the first reported advance in adjuvant endocrine therapy for this setting in roughly 20 years.
- Comparison limitations: The trial did not compare giredestrant against regimens incorporating CDK4/6 inhibitors, leaving its place relative to these newer standards unresolved.
- Cost and adoption concerns: Investigators expressed enthusiasm about the efficacy signal but noted potential concerns regarding drug cost and its impact on real-world adoption.